Atossa Genetics (ATOS) Competitors $4.84 +0.10 (+2.11%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$4.82 -0.01 (-0.31%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. PRQR, ADAG, IMUX, ABOS, and PLXShould you buy Atossa Genetics stock or one of its competitors? MarketBeat compares Atossa Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atossa Genetics include ProQR Therapeutics (PRQR), Adagene (ADAG), Immunic (IMUX), Acumen Pharmaceuticals (ABOS), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. ATOS vs. PRQRATOS vs. ADAGATOS vs. IMUXATOS vs. ABOSATOS vs. PLXHow does Atossa Genetics compare to ProQR Therapeutics?Atossa Genetics (NASDAQ:ATOS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Which has stronger earnings and valuation, ATOS or PRQR? Atossa Genetics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$34.77M-$3.21N/AProQR Therapeutics$17.99M8.37-$47.73M-$0.50N/A Is ATOS or PRQR more profitable? Atossa Genetics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -84.91% -72.36% ProQR Therapeutics -331.33%-84.87%-37.78% Do insiders & institutionals have more ownership in ATOS or PRQR? 12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer ATOS or PRQR? Atossa Genetics presently has a consensus price target of $36.33, suggesting a potential upside of 650.69%. ProQR Therapeutics has a consensus price target of $7.25, suggesting a potential upside of 406.99%. Given Atossa Genetics' higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media prefer ATOS or PRQR? In the previous week, Atossa Genetics had 4 more articles in the media than ProQR Therapeutics. MarketBeat recorded 9 mentions for Atossa Genetics and 5 mentions for ProQR Therapeutics. Atossa Genetics' average media sentiment score of 0.65 beat ProQR Therapeutics' score of 0.20 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive ProQR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ATOS or PRQR? Atossa Genetics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. SummaryAtossa Genetics beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.How does Atossa Genetics compare to Adagene?Adagene (NASDAQ:ADAG) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Which has stronger valuation & earnings, ADAG or ATOS? Adagene has higher revenue and earnings than Atossa Genetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$7.67M21.31-$17.61MN/AN/AAtossa GeneticsN/AN/A-$34.77M-$3.21N/A Does the media refer more to ADAG or ATOS? In the previous week, Atossa Genetics had 8 more articles in the media than Adagene. MarketBeat recorded 9 mentions for Atossa Genetics and 1 mentions for Adagene. Atossa Genetics' average media sentiment score of 0.65 beat Adagene's score of 0.15 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, ADAG or ATOS? Adagene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Do institutionals & insiders hold more shares of ADAG or ATOS? 9.5% of Adagene shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 9.8% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ADAG or ATOS more profitable? Adagene's return on equity of 0.00% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Atossa Genetics N/A -84.91%-72.36% Do analysts rate ADAG or ATOS? Adagene presently has a consensus price target of $8.00, suggesting a potential upside of 131.88%. Atossa Genetics has a consensus price target of $36.33, suggesting a potential upside of 650.69%. Given Atossa Genetics' higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 SummaryAdagene beats Atossa Genetics on 7 of the 12 factors compared between the two stocks.How does Atossa Genetics compare to Immunic?Atossa Genetics (NASDAQ:ATOS) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Is ATOS or IMUX more profitable? Atossa Genetics' return on equity of -84.91% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -84.91% -72.36% Immunic N/A -220.75%-132.04% Do analysts rate ATOS or IMUX? Atossa Genetics currently has a consensus target price of $36.33, suggesting a potential upside of 650.69%. Immunic has a consensus target price of $50.86, suggesting a potential upside of 340.32%. Given Atossa Genetics' higher probable upside, equities research analysts clearly believe Atossa Genetics is more favorable than Immunic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Immunic 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 3.00 Which has more volatility and risk, ATOS or IMUX? Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Immunic has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Does the media refer more to ATOS or IMUX? In the previous week, Immunic had 9 more articles in the media than Atossa Genetics. MarketBeat recorded 18 mentions for Immunic and 9 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.65 beat Immunic's score of -0.13 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Immunic 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in ATOS or IMUX? 12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 14.0% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ATOS or IMUX? Immunic is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$34.77M-$3.21N/AImmunicN/AN/A-$97.17M-$5.58N/A SummaryAtossa Genetics beats Immunic on 8 of the 14 factors compared between the two stocks.How does Atossa Genetics compare to Acumen Pharmaceuticals?Acumen Pharmaceuticals (NASDAQ:ABOS) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is ABOS or ATOS more profitable? Atossa Genetics' return on equity of -84.91% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -123.07% -79.41% Atossa Genetics N/A -84.91%-72.36% Which has preferable valuation & earnings, ABOS or ATOS? Atossa Genetics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$121.33M-$1.86N/AAtossa GeneticsN/AN/A-$34.77M-$3.21N/A Which has more volatility & risk, ABOS or ATOS? Acumen Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Does the media favor ABOS or ATOS? In the previous week, Atossa Genetics had 5 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 9 mentions for Atossa Genetics and 4 mentions for Acumen Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.65 beat Acumen Pharmaceuticals' score of -0.05 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ABOS or ATOS? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate ABOS or ATOS? Acumen Pharmaceuticals currently has a consensus target price of $6.67, suggesting a potential upside of 183.69%. Atossa Genetics has a consensus target price of $36.33, suggesting a potential upside of 650.69%. Given Atossa Genetics' higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 SummaryAtossa Genetics beats Acumen Pharmaceuticals on 9 of the 14 factors compared between the two stocks.How does Atossa Genetics compare to Protalix BioTherapeutics?Atossa Genetics (NASDAQ:ATOS) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Which has more volatility and risk, ATOS or PLX? Atossa Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Do institutionals & insiders have more ownership in ATOS or PLX? 12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ATOS or PLX more profitable? Atossa Genetics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -84.91% -72.36% Protalix BioTherapeutics -21.03%-30.89%-11.74% Which has higher valuation & earnings, ATOS or PLX? Protalix BioTherapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$34.77M-$3.21N/AProtalix BioTherapeutics$76.38M2.12$8.31M$0.1811.17 Do analysts recommend ATOS or PLX? Atossa Genetics currently has a consensus price target of $36.33, suggesting a potential upside of 650.69%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 497.01%. Given Atossa Genetics' higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Protalix BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ATOS or PLX? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 9 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.65 beat Protalix BioTherapeutics' score of 0.44 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAtossa Genetics and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition ExportMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.86M$7.03B$6.30B$12.11BDividend YieldN/A1.70%2.80%5.36%P/E Ratio-1.5150.5320.8225.31Price / SalesN/A73.13514.3771.03Price / CashN/A24.4043.1855.00Price / Book1.376.429.886.94Net Income-$34.77M$158.81M$3.55B$335.25M7 Day Performance-6.02%1.46%-0.83%-1.39%1 Month Performance-16.12%-1.46%-1.19%0.09%1 Year Performance-62.94%1.61%33.66%32.51% Atossa Genetics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics3.1216 of 5 stars$4.84+2.1%$36.33+650.7%-65.8%$40.86MN/AN/A8News CoveragePRQRProQR Therapeutics3.3938 of 5 stars$1.50-0.7%$7.25+383.3%-18.8%$162.25M$17.99MN/A180ADAGAdagene2.6094 of 5 stars$3.42+0.7%$8.00+134.3%+121.2%$161.84M$7.67MN/A260Gap UpIMUXImmunic3.8188 of 5 stars$11.58-0.7%$50.86+339.0%+18.6%$157.77MN/AN/A70Trending NewsAnalyst RevisionABOSAcumen Pharmaceuticals2.1494 of 5 stars$2.15-1.6%$6.67+210.7%+121.7%$155.00MN/AN/A20Gap Up Related Companies and Tools Related Companies PRQR Alternatives ADAG Alternatives IMUX Alternatives ABOS Alternatives PLX Alternatives MENS Alternatives ASRT Alternatives MOLN Alternatives OGI Alternatives CNTB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
